Venus Remedies rises on getting oncology tender from PAHO
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Venus Remedies is currently trading at Rs. 377.80, up by 3.05 points or 0.81% from its previous closing of Rs. 374.75 on the BSE.
The scrip opened at Rs. 376.75 and has touched a high and low of Rs. 394.45 and Rs. 376.75 respectively. So far 12516 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 222.00 on 23-Aug-2023.
Last one week high and low of the scrip stood at Rs. 394.45 and Rs. 359.50 respectively. The current market cap of the company is Rs. 505.00 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.48% and 56.76% respectively.
Venus Remedies has been awarded an oncology tender by the WHO-backed Pan American Health Organisation (PAHO), the world’s oldest international public health agency, for supplying essential cancer drugs to multiple Latin American countries. This achievement signifies a major milestone for the company, enhancing its contribution to global health initiatives and reinforcing its commitment to improving global health outcomes by providing life-saving medicines to those who need them the most.
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs like bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate, and vincristine. This prestigious tender award highlights Venus Remedies' commitment to advancing healthcare and its crucial role in the global battle against cancer.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
